Founded in 2016, Prolifagen is an early-stage biotech startup whose mission is to prevent the development of heart failure in patients with large myocardial infarcts. It currently has a microRNA therapeutic, miR-302, that has been successful in inducing regeneration of heart muscle during the first month after infarct in mouse and pig models. It plans to begin clinical studies soon. Visit Prolifagen.com for more information.
Company Details
- Employees
- 3
- Founded
- 2016
- Address
- Philadelphia, Pa, Us
- Industry
- Biotechnology
- Website
- https://prolifagen.com/
- Keywords
- West Chester.
- HQ
- Philadelphia, PA
Prolifagen Questions
Prolifagen's website is https://prolifagen.com/
Prolifagen's LinkedIn profile is https://www.linkedin.com/company/prolifagen
Prolifagen has
3 employees.
View email and phone details for 3
employees at Prolifagen.
Prolifagen's industry is
Biotechnology
Prolifagen's top competitors are
Fathom Pharma,
Incuta Therapeutics,
Flobio Llc,
Neurokappa Therapeutics Llc,
Hbo2 Therapeutics,
Gunner Goggles™,
Estrenón,
Archimedic,
Annovis Bio, Inc.,
Bankers Crowdcredit Funding Co., Ltd. (Former Crowd Credit, Inc.).
Prolifagen's categories are Biotechnology
Prolifagen's founding year is 2016
